Henry Schein (NASDAQ:HSIC) Reaches New 12-Month High – Here’s Why

Henry Schein, Inc. (NASDAQ:HSIC)’s stock price reached a new 52-week high during trading on Thursday . The stock traded as high as $82.73 and last traded at $82.5250, with a volume of 82315 shares changing hands. The stock had previously closed at $81.69.

Analyst Upgrades and Downgrades

Several analysts have issued reports on HSIC shares. Morgan Stanley increased their price objective on shares of Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a research report on Wednesday, November 5th. Evercore boosted their price objective on shares of Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Weiss Ratings restated a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Wells Fargo & Company raised their price objective on Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 5th. Finally, Mizuho set a $81.00 target price on shares of Henry Schein and gave the company a “neutral” rating in a research note on Tuesday, January 20th. Five research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $76.42.

Henry Schein Trading Down 2.8%

The company has a current ratio of 1.40, a quick ratio of 0.79 and a debt-to-equity ratio of 0.54. The stock has a market cap of $9.35 billion, a P/E ratio of 25.12, a PEG ratio of 2.41 and a beta of 0.88. The firm’s 50-day simple moving average is $76.90 and its 200 day simple moving average is $71.18.

Institutional Trading of Henry Schein

Hedge funds and other institutional investors have recently modified their holdings of the company. Artisan Partners Limited Partnership grew its holdings in shares of Henry Schein by 5.7% in the 3rd quarter. Artisan Partners Limited Partnership now owns 6,833,041 shares of the company’s stock worth $453,509,000 after acquiring an additional 370,837 shares during the last quarter. Invesco Ltd. increased its stake in Henry Schein by 4.1% in the 3rd quarter. Invesco Ltd. now owns 4,731,698 shares of the company’s stock worth $314,043,000 after purchasing an additional 184,763 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Henry Schein by 6.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,596,168 shares of the company’s stock worth $172,304,000 after purchasing an additional 159,087 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Henry Schein by 11.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,523,014 shares of the company’s stock worth $167,453,000 after buying an additional 256,156 shares during the period. Finally, Bank of Montreal Can lifted its stake in Henry Schein by 3,655.7% during the fourth quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after buying an additional 2,087,666 shares in the last quarter. Institutional investors own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.